Cargando…

Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure

OBJECTIVE: The objective of this study was to assess the pharmacokinetic and pharmacodynamic profiles and safety of edoxaban in patients with nonvalvular atrial fibrillation (NVAF) who were hospitalized with acute heart failure (AHF). METHODS: The trough plasma concentrations of edoxaban, and the co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nabeta, Takeru, Kida, Keisuke, Ishida, Miwa, Shiono, Takaaki, Suzuki, Norio, Doi, Shunichi, Tsukahara, Maya, Ohta, Yuki, Kimura, Tetsuya, Yamaguchi, Keita, Takita, Atsushi, Matsumoto, Naoki, Akashi, Yoshihiro J., Ako, Junya, Inomata, Takayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332564/ https://www.ncbi.nlm.nih.gov/pubmed/33782831 http://dx.doi.org/10.1007/s40262-021-00999-y

Ejemplares similares

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
por: Ikushima, Ippei, et al.
Publicado: (2020)

An Irreversible Worsening Cardiac Function after Withdrawing Medical Treatments in a Patient with Dilated Cardiomyopathy: A Pathological Analysis
por: Yazaki, Mayu, et al.
Publicado: (2020)

Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022)

Response to letter to the editor entitled “Association between left atrial sphericity index and clinical outcomes in patients with systolic heart failure”
por: Yazaki, Mayu, et al.
Publicado: (2021)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
por: Acharya, Tushar, et al.
Publicado: (2015)

Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016)

Tako-tsubo-like left ventricular dysfunction in a patient with COVID-19 demonstrated by non-invasive multi-modality imaging
por: Fujiyoshi, Kazuhiro, et al.
Publicado: (2020)

Late gadolinium enhancement for re‐worsening left ventricular ejection fraction in patients with dilated cardiomyopathy
por: Nabeta, Takeru, et al.
Publicado: (2020)

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure
por: Yazaki, Mayu, et al.
Publicado: (2019)

Clinical significance of left atrial geometry in dilated cardiomyopathy patients: A cardiovascular magnetic resonance study
por: Yazaki, Mayu, et al.
Publicado: (2020)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
por: Alsultan, Mohammed M., et al.
Publicado: (2023)

Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): Three‐month interim analysis results
por: Yamashita, Takeshi, et al.
Publicado: (2018)

Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF‐Japan): One‐year safety and effectiveness analyses
por: Yamashita, Takeshi, et al.
Publicado: (2020)

Editorial to the Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA‐AF Japan): One‐year safety and effectiveness analyses
por: Nagashima, Koichi, et al.
Publicado: (2020)

Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two‐year postmarketing surveillance study (ETNA‐AF‐Japan)
por: Yamashita, Takeshi, et al.
Publicado: (2021)

Factors associated with bleeding events during catheter ablation with uninterrupted periprocedural edoxaban for atrial fibrillation: a subanalysis of the KYU-RABLE study
por: Abe, Ichitaro, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
por: Hara, Nobuhiro, et al.
Publicado: (2017)

Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
por: Mikami, Takeshi, et al.
Publicado: (2022)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Changes in plasma concentrations of edoxaban and coagulation biomarkers according to thromboembolic risk and atrial fibrillation type in patients undergoing catheter ablation: Subanalysis of KYU‐RABLE
por: Shinohara, Tetsuji, et al.
Publicado: (2020)

Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure
por: Ikeda, Yuki, et al.
Publicado: (2021)

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution
por: Xu, Ruijuan, et al.
Publicado: (2023)

Clinical valuables related to resolution of complete or advanced atrioventricular block after steroid therapy in patients with cardiac sarcoidosis
por: Nabeta, Takeru, et al.
Publicado: (2021)

Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2023)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Variation in heart rate range by 24‐h Holter monitoring predicts heart failure in patients with atrial fibrillation
por: Oikawa, Jun, et al.
Publicado: (2022)

Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban
por: Toratani, Mizuho, et al.
Publicado: (2017)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

Edoxaban was Effective for Treating Renal Vein Thrombosis in a Patient with Nephrotic Syndrome
por: Shimada, Yoshitaka, et al.
Publicado: (2017)

Native T1 high region and left ventricular ejection fraction recovery in patients with dilated cardiomyopathy
por: Yazaki, Mayu, et al.
Publicado: (2023)

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study
por: Xiang, Qian, et al.
Publicado: (2022)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Sensory evaluation of edoxaban orally disintegrating tablets: an open-label interventional study (secondary publication)
por: Yamashita, Takeshi, et al.
Publicado: (2019)

Preventing thrombosis in a COVID‐19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation
por: Doi, Shunichi, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Efficacy and Safety of Home-Based Cardiac Telemonitoring Rehabilitation in Patients After Transcatheter Aortic Valve Implantation: Single-Center Usability and Feasibility Study
por: Ashikaga, Kohei, et al.
Publicado: (2023)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vo3tc5atdd3pdpvb897qf70m6f